Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Jan 10, 2023 2:57pm
260 Views
Post# 35214067

It seems like..

It seems like..

 

That it’s not only THTX who believes two long acting drugs regime is the path forward…

 

“However, despite findings of efficacy in studies when given daily, weekly, or as an injection up to every 6 months, lenacapavir is dependent on antiretroviral drugs that must be given daily.

 

These are undoubtedly promising results; however, lenacapavir needs a long-acting partner if it is to deliver on its promise of being part of a comprehensive long-acting regimen,” noted Chloe Orkin, MBBCH, of the University Queen Mary in London, writing in a commentary accompanying the study. "With the development of islatravir slowed by unexpected immunological findings, the identity of this partner is far from clear."

 

https://lesactualites.news/sante/medicament-anti-vih-a-action-prolongee-prometteur-pour-les-patients-naifs-de-traitement/

<< Previous
Bullboard Posts
Next >>